MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcin.2012.12.118

Медицинская библиотека · JACC. Cardiovascular interventions · 2013

Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.

Zeller Thomas, Dake Michael D, Tepe Gunnar, Brechtel Klaus, Noory Elias, Beschorner Ulrich, Kultgen Patricia L, Rastan Aljoscha

Клиническое исследованиеСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

This study sought to evaluate the outcomes of drug-eluting stent treatment for femoropopliteal in-stent restenosis (ISR).

BACKGROUND

ISR after femoropopliteal interventions is an increasing problem. Although the role of drug-eluting stents in the treatment of coronary ISR is well defined, no published studies have examined drug-eluting stents in the treatment of femoropopliteal ISR.

METHODS

This study examines 108 patients with 119 ISR lesions who were enrolled in the ZILVER-PTX single-arm study, a prospective, multicenter clinical trial of 787 patients. All patients were treated with paclitaxel-eluting nitinol stents.

RESULTS

Mean patient age was 68.3 ± 9.4 years; 61.1% of patients were men. Mean lesion length was 133.0 ± 91.7 mm; 33.6% of lesions were >150 mm long and 31.1% of lesions were totally occluded. Procedural success was achieved in 98.2% of lesions with 2.1 ± 1.2 stents placed per lesion. Primary patency was 95.7% at 6 months and 78.8% at 1 year. Freedom from target lesion revascularization was 96.2% at 6 months, 81.0% at 1 year, and 60.8% at 2 years. Forty patients experienced major adverse events, exclusively target lesion revascularization. Before treatment, 81.1% of patients had Rutherford scores ≥3; at 2 years, 60.9% of patients had Rutherford scores ≤1. Both ankle brachial index and walking impairment questionnaire scores significantly improved following treatment. The 1-year fracture rate of stents used in ISR lesions was 1.2%. No significant risk factors associated with loss of patency were identified.

CONCLUSIONS

Treatment of femoropopliteal ISR with paclitaxel-eluting stents results in favorable acute, midterm, and long-term outcomes. (Zilver PTX Global Registry [ZILVER-PTX]; NCT01094678).

Для цитирования: Zeller Thomas, Dake Michael D, Tepe Gunnar, Brechtel Klaus, Noory Elias, Beschorner Ulrich, Kultgen Patricia L, Rastan Aljoscha. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.. JACC. Cardiovascular interventions. 2013. DOI: 10.1016/j.jcin.2012.12.118.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.